Document:

EX-10.10

 Exhibit 10.10 

CONFIDENTIAL TREATMENT REQUESTED 

EXCLUSIVE PATENT LICENSE AGREEMENT 

This exclusive patent license agreement (“Agreement”) is dated and effective as of the date of last signature (the “Effective
Date”), and is made between the University of Washington, a public institution of higher education and an agency of the state of Washington, acting through UW CoMotion (“University”), and Solid GT, LLC, a limited liability company
under the laws of the state of Delaware (“Company”), (individually “Party” or collectively “Parties”). 

Background 
 Certain
inventions related to Novel micro-dystrophins under muscle-specific promoters for the treatment of Duchenne Muscular Dystrophy were made in the laboratory of Dr. Jeffrey Chamberlain (“Principal Investigator”); 

As assignee of the inventions, University owns the patents and patent applications as listed in Section A1 “Licensed Patents” of
Exhibit A “Exclusive Patent License Schedule” and University has the right to license to others certain rights to such patents and patent applications;     

Whereas University and Company entered into a confidentiality agreement with the effective date of June 16th, 2014 with University reference number 35111A; 
 Whereas University and Company entered
into an exclusive option agreement for Licensed Patents with the effective date of February 5, 2015 with University reference number 36201A;  

Company desires that University grant it an exclusive license to use, develop, and commercialize the inventions claimed in the Licensed
Patents; and 
 University is willing to grant a license on the terms set forth below. 

The Parties therefore agree as follows: 
  

	1.	Definitions. 

 For purposes of interpreting this Agreement, the following terms have the
following meanings ascribed to them: 
 1.1. “Assignment” means (A) the sale by Company of all but no less than
all of its assets to an arm’s length Third Party, (B) the sale, transfer, or exchange by the shareholders, partners, or equity owners of Company of a majority interest in Company to an arm’s length Third Party, or (C) the merger
of Company into an arm’s length Third Party. 
 1.2. “Assignment Consideration” means all consideration received by Company
for an Assignment. 

  

							
		  	 	Page 1 of 21	 	 	

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 1.3. “Confidential Information” means any information or materials (biological,
chemical, or otherwise) of the Parties not generally known to the public, including any information comprised of those materials, and including without limitation the inventions covered by the Licensed Patents and Company’s business plans or
reports. Confidential Information does not include any information that: 
 1.3.1. is or becomes part of the public domain
through no fault of receiving Party; 
 1.3.2. is known to receiving Party prior to the disclosure by the disclosing Party,
as evidenced by documentation; 
 1.3.3. is publicly released as authorized under this Agreement by University, its employees
or agents; 
 1.3.4. is subsequently obtained by a Party from a Third Party who is authorized to have such information; or

 1.3.5. is independently developed by a Party without reliance on any portion of the Confidential Information received from
the disclosing Party and without any breach of this Agreement as evidenced by documentation. 
 1.4. “Event of Force Majeure”
means an unforeseeable act that wholly prevents a Party from performing one or more of its material duties under this Agreement and that is outside of the reasonable control of the Party. An Event of Force Majeure includes acts of war or of Nature,
insurrection and riot, and labor strikes. An Event of Force Majeure does not mean a Party’s inability to obtain a Third Party’s consent to any act or omission. 

1.5. “Field of Use” means Treatment of Duchenne Muscular Dystrophy and related disease indications caused by a lack of functional
dystrophin. 
 1.6. “Licensed Patents” means the patents and patent applications (including all provisional,
nonprovisional, and PCT patent applications, and all national stage and foreign equivalents of the foregoing, accordingly) listed in Section A1 “Licensed Patents” of attached Exhibit A “Exclusive Patent License Schedule”, all
divisionals and continuations of these patent applications, all patents issuing from these applications, divisionals, and continuations and any reissues, reexaminations, supplementary protection certificates and extensions of these patents, and any
corresponding foreign applications or patents thereof. Claims in continuations-in-part applications are included in Licensed Patents only to the extent such claims are
supported by a patent or patent application set forth in Section A1 “Licensed Patents” of Exhibit A “Exclusive Patent License Schedule” to benefit from the priority date of such patent or patent application and to the extent such
claims are not encumbered by Third Party rights.  
 1.7. “Licensed Product” means any product or good that is used, made
by, made for, sold, transferred, offered for sale, imported or otherwise disposed of during the term of this Agreement and for which use, manufacture, sale, transfer is covered by one or more Valid Claims of the Licensed Patents. 

1.8. “Net Sales” means the gross amount invoiced or otherwise received by Company or Sublicensee for sales, leases, and other
dispositions of Licensed Products less (i) all trade, quantity, and cash discounts actually allowed, (ii) all credits and allowances actually granted due to rejections, returns, billing errors, and retroactive price reductions,
(iii) duties, and (iv) excise, sale and use taxes, and equivalent taxes to the extent not reimbursable. On sales of Licensed Products by Company to Sublicensees or on sales made in other than an arm’s length transactions, the value of
the Net Sales attributed to such transaction shall be that which would have been received in an arm’s length transaction, based on sales of like quantity and quality products on or about the time of this transaction. 

  

							
		  	 	Page 2 of 21	 	 	

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 1.9. “Patent Expenses” means all reasonable costs (including attorneys’ and
application fees) incurred by University to apply for, prosecute, enforce, and maintain Licensed Patents including the costs of interferences, oppositions, re-examinations, and patent litigation. For clarity,
patent litigation may result in a positive cash position from damages and therefore is subject to distribution rights of the Parties of Article 7. 

1.10. “Sublicense” means the grant by Company to a Third Party of any license, option, first right to negotiate, or
other right granted under the Licensed Patents, in whole or in part. For the avoidance of doubt, any arm’s length Third Party distributor (“Distributor”) to which Company or any of its Sublicensees sells a Licensed Product for resale
of Licensed Product by the Distributor, and where Distributor has no other rights other than to resell Licensed Product, and for which resale Company and Sublicensees receive no further consideration (including but not limited to royalties and/or
commissions) beyond the price for the initial sale to the Distributor shall not be a considered a Sublicense. 
 1.11.
“Sublicensee” means a Third Party holding a Sublicense under the Licensed Patents. 
 1.12. “Sublicensing Consideration”
means all consideration, including but not limited to upfront fees, milestone payments, maintenance fees, non cash consideration, and premiums over Fair Market Value of stock, but excluding royalties, payable by each Sublicensee and attributable to
the grant of a Sublicense. For avoidance of doubt, the following are not deemed to be Sublicensing Consideration: (A) consideration paid to Company by Sublicensees for the performance of bona fide product development work, research work,
clinical studies and regulatory approvals performed by Company, pursuant to and as supported by an express agreement including a performance plan and commensurate budget; (B) payments made as consideration for the issuance of equity or debt
securities of Company at fair market value; and (C) contractually required reimbursement of payment amounts otherwise due under this Agreement from Company to University for Patent Expenses pursuant to Section A4 (Patent Expense Payment); and
(D) to the extent a milestone under Section A3.5 (Financial Milestones) of this Agreement is met by the Sublicensee, any pass-through payment to Company that ultimately comes to University for such milestone payment. 

1.13. “Territory” means worldwide. 

1.14. “Third Party” means an individual or entity other than University and Company. 

1.15. “Valid Claim” means (i) a claim in an issued and unexpired patent included in the Licensed Patents that: (a) has not
been held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction, and not subject to appeal, (b) has not been admitted to be invalid or unenforceable through reissue or disclaimer
or otherwise, (c) has not been lost through an interference, reexamination, or reissue proceeding; or (ii) a claim of a pending patent application included in the Licensed Patents that has not been abandoned or finally rejected without the
possibility of appeal or refiling and that has been pending for less than five (5) years from its priority date. 
  

	2.	Term. 

 The term of this Agreement will commence on the Effective Date and, unless
terminated earlier as provided in Article 9 “Termination”, will expire on the date on which no Valid Claim in a Licensed Patent is pending or subsisting in any country in the Territory. 

  

							
		  	 	Page 3 of 21	 	 	

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

	3.	Grant of License. 

 3.1. Company’s Rights. 

3.1.1. License Grant. Subject to the terms and conditions of this Agreement, University hereby grants to Company, and
Company hereby accepts, an exclusive license to make, have made on Company’s behalf, use, offer to sell or sell, offer to lease or lease, import, or otherwise offer to dispose or dispose of Licensed Products in the Territory in the Field of
Use. The license granted in this Agreement is limited to the inventions that are expressly claimed in the Licensed Patents. No provision of this Agreement grants Company, by implication, estoppel or otherwise, any rights other than the rights
expressly granted it in this Agreement to the Licensed Patents, or to any other University-owned technology, patent applications, or patents. 

3.1.2. Sublicenses. Company has the right, exercisable from time to time during the term of this Agreement, to
Sublicense its rights under this Agreement; Company may grant Sublicensees the right to grant sublicenses but not the right to enforce Licensed Patents. Company shall remain responsible for its obligations under this Agreement, and shall ensure that
the Sublicense agreement: i) contains terms and conditions requesting Sublicensee to comply with the applicable terms and conditions under this Agreement (including a release substantially similar to that provided by Company in Section 10.1
“Company’s Release”; a warranty substantially similar to that provided by Company in Section 11.1 “Authority”; University disclaimers and exclusions of warranties under Subsections 11.2 “Disclaimers”; and
limitations of remedies and damages substantially similar to those provided by Company in Sections 12.1 “Remedy Limitation” and 12.2 “Damage Cap”); and (ii) specifically incorporates provisions of this Agreement regarding
obligations pertaining to indemnification, use of names and insurance. Company shall deliver to University a true, correct, and complete copy of any Sublicense agreement or other agreement under which Company purports or intends to grant Sublicense
rights at least 20 business days prior to the execution of the agreement, along with a request for review within 20 days pursuant to this Subsection 3.1.2 “Sublicenses”. University will review the unexecuted Sublicense and will, within 20
business days of receipt of the proposed Sublicense, either provide express written approval for the Sublicense as presented or decline consent for the transaction. Such approval will not be unreasonably withheld. If approval is granted, Company
will provide University copies of the Sublicense agreement within 30 days of its execution. Company shall not enter into such agreement if the terms of the agreement are inconsistent in any respect with the material terms of this Agreement. Any
Sublicense made in violation of this Subsection will be void and will constitute an event of default under Subsection 9.1.1 “Breach by Company”. 

3.2. The United States Government’s Rights. The inventions covered in the Licensed Patents arose, in whole or in part, from
federally supported research and the federal government of the United States of America has certain rights in and to the Licensed Patents as those rights are described in Chapter 18, Title 35 of the United States Code and accompanying regulations,
including Part 401, Chapter 37 of the Code of Federal Regulation. The Parties’ rights and obligations under this Agreement to any government-funded inventions, including the grant of license set forth in Subsection 3.1.1, are subject to the
applicable terms of the aforementioned United States laws. 
 3.3. University’s Reservation of Rights. University reserves all
rights not expressly granted to Company under this Agreement. University retains for itself an irrevocable, nonexclusive license to make, have made, and use products, processes, and other subject matter covered by the Licensed

  

							
		  	 	Page 4 of 21	 	 	

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
Patents in the Field of Use for academic research, medical, instructional, or any other academic purpose. Expressly included within this University reservation of rights is the right (i) to
use the Licensed Patents in sponsored research or collaborative research with any Third Party but only to the extent no such Third Party is granted any rights to the Licensed Patents or to commercialize Licensed Products, (ii) to grant material
transfer agreements to materials whose composition of matter is covered by the Licensed Patents where the use of such materials is restricted to academic research, medical, instructional, or any other academic purpose, and (iii) to publish any
information included in the Licensed Patents or any other information that may result from University’s research. 
 3.4.
Reservation of Rights for Humanitarian Purposes. Consistent with 35 U.S.C. §200 et seq., University retains the right to require Company to grant Sublicenses to responsible applicants in the Field of Use under the Licensed Patents on
terms that are reasonable under the circumstances; or, if Company fails to grant a license, to grant the license itself. The exercise of these rights by University will only be in exceptional circumstances and only if University determines
(i) the action is necessary to meet health or safety needs that are not reasonably satisfied by Company; or (ii) the action is necessary to meet requirements for public use specified by federal regulations, and such requirements are not
reasonably satisfied by Company. University shall not require the granting of a sublicense, and shall not grant the license itself, unless the responsible applicant has first negotiated in good faith with Company. 

 

	4.	Applications and Patents. 

 4.1. Pre-Agreement
Patent Filings and Licensed Product Sales. Company has reviewed the Licensed Patents and represents that it is not aware of any basis to challenge or dispute the inventorship, validity, or enforceability of any of the claims made in the Licensed
Patents in existence as of the Effective Date. Company further represents that, as of the Effective Date, it has not and does not manufacture, have manufactured, use, offer to sell or sell, offer to lease or lease, import, or otherwise offer to
dispose or dispose of (a) any product or good that infringes (including under the doctrine of equivalents) a claim in any Licensed Patent, or (b) any product or good that is made using a process or machine that infringes (including under
the doctrine of equivalents) a claim in a Licensed Patent. 
 4.2. Patent Application Filings during the Term of this Agreement. 

4.2.1. University Prosecutes Patents. University retains the sole and exclusive right to file or otherwise prosecute
Licensed Patents, in consultation with the Company pursuant to Section 4.2.2. As set out in Section A4 “Patent Cost Reimbursement” of Exhibit A “Exclusive Patent License Schedule”, Company shall pay, or reimburse University
for paying, all Patent Expenses incurred prior to, on, or after the Effective Date.     
 4.2.2.
Patent Prosecution Decisions. University, in consultation with Company, shall determine in which countries University will file, or cause to be filed, Licensed Patents. University shall request patent counsel to inform Company of the status
of the prosecution of the Licensed Patents, including delivering to Company written and electronic communications from all patent offices and foreign counsel, and University shall consult with the Company on the prosecution of the Licensed Patents.
Once Company begins reimbursing University for Patent Expenses pursuant to Section A4 “Patent Cost Reimbursement” of Exhibit A “Exclusive Patent License Schedule”, Company’s suggestions and requests regarding patent
prosecution will be reasonably considered and included unless detrimental to University’s intellectual property rights. In no event shall Company file a patent application where all of the inventors are under University policy obligated to

  

							
		  	 	Page 5 of 21	 	 	

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
assign their rights in such patent application to University. In no event shall Company file a patent application where one or more, but not all, of the inventors are under University policy
obligated to assign their rights in such patent application to University without University’s prior consent which shall not be unreasonably withheld or delayed. 

4.2.3. University’s Independent Patent Filings. At its sole expense, University may file, prosecute or maintain
Licensed Patents in any country in which Company has not requested University to file, prosecute or maintain such Licensed Patents in accordance with this Article 4 “Applications and Patents” and those applications and resultant patents
will not be subject to this Agreement. 
 4.2.4. No Limitation on University’s Right to Prosecute Patents. No
provision of this Agreement limits, conditions, or otherwise affects University’s right to prosecute Licensed Patents in any country, except as expressly provided herein. 

4.3. Maintenance of Licensed Patents. Subject to Company’s compliance with Section A4 “Patent Cost Reimbursement” of
attached Exhibit A “Exclusive Patent License Schedule”, University shall take all commercially reasonable steps to cause each Licensed Patent to remain or be valid and subsisting. 

4.4. Ownership of the Licensed Patents. No provision of this Agreement grants Company any rights, titles, or interests (except for the
grant of license in Subsection 3.1.1 “License Grant” of this Agreement) in the Licensed Patents, notwithstanding Company’s payment of all or any portion of the patent prosecution, maintenance, and related costs. 

 

	5.	Commercialization. 

 5.1. Commercialization and Performance Milestones. Company
shall use its commercially reasonable efforts, consistent with sound and reasonable business practices and judgment, to commercialize the inventions covered by the Licensed Patents and to make and sell Licensed Products as soon as practicable and to
maximize sales thereof. Unless an extension is provided due to the occurrence of an Event of Force Majeure during the term of this Agreement, Company shall perform, or shall cause to happen or be performed, the performance milestones described in
Section A2 “Performance Milestones” of attached Exhibit A “Exclusive Patent License Schedule”. 
 5.2. Covenants
Regarding the Manufacture of Licensed Products. Company hereby covenants and agrees that the manufacture, use, sale, or transfer of Licensed Products will comply with all applicable federal and state laws, including all federal export laws and
regulations. Company hereby further covenants and agrees that, to the extent required by 35 United States Code Section 204, it shall, and it shall cause each Sublicensee, to substantially manufacture in the United States of America all products
embodying or produced through the use of an invention that is subject to the rights of the federal government of the United States of America. 

5.3. Commercialization Reports. Within 30 days of the anniversary of the Effective Date of each year during the term of this Agreement,
Company shall deliver to University written reports of Company’s and Sublicensees’ efforts and plans to commercialize the inventions covered by the Licensed Patents and to make, have made on its behalf, use, offer to sell or sell, offer to
lease or lease, import, or otherwise offer to dispose or dispose of Licensed Products. Company shall not be obligated to prepare such commercialization reports in years Company or Sublicensee delivers to University a written sales

  

							
		  	 	Page 6 of 21	 	 	

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
report under Section 6.4 “Sales Reports” and will resume if sales of Licensed Products ceases. In relation to each of the performance milestones described in Section A2
“Performance Milestones” of attached Exhibit A “Exclusive Patent License Schedule”, each commercialization report will include sufficient information to demonstrate compliance of those performance milestones and will set out
timeframes and plans for those which have not yet been met. 
 5.4. Use of University’s Name and Trademarks or the Names of
University Faculty, Staff, or Students. No provision of this Agreement grants Company or Sublicensee any right or license to use the name or trademarks of University or the names or identities of any member of the faculty, staff, or student body
of University. Company shall not use, and shall not permit a Sublicensee to use, any such trademarks, names, or identities without University’s and, as the case may be, such member’s prior written approval. 

 

	6.	Payments, Reimbursements, Reports, and Records. 

 6.1. Payments. Company shall
deliver to University the payments specified in Sections A3 “Payments” and A4 “Patent Cost Reimbursement” of attached Exhibit A “Exclusive Patent License Schedule”. Company shall make such payments by check, wire
transfer, or any other mutually agreed-upon and generally accepted method of payment. All checks to University will be made payable to “University of Washington” and will be mailed to the address specified in Article 21 “Notices”
of this Agreement and will include the University agreement number 37475A. Upon request, University shall deliver to Company written wire transfer instructions. 

6.2. Currency and Checks. All computations and payments made under this Agreement will be in United States dollars. The exchange rate
for the currency into dollars as reported in the Wall Street Journal as the New York foreign exchange mid-range rate on the last business day of the month in which the transaction was entered into will
be used for determining the dollar value of transactions conducted in non-United States dollar currencies. 

6.3. Late Payments. University may charge Company a late fee for all amounts owed to University that are overdue by 30 days or more.
The late fee will be computed as the United States prime rate plus [XXX], as set forth by The Wall Street Journal (Western edition) of the outstanding, unpaid balance. The payment of a late fee will not foreclose or limit University from
exercising any other rights it may have as a consequence of the lateness of any payment. 
 6.4. Sales Reports. Within 30 days after
the last day of each calendar quarter commencing the calendar quarter after Company effects its first commercial sale of a Licensed Product and during the term of this Agreement, Company shall deliver to University a written sales report (a copy of
the form of which is attached as Exhibit B “Royalty Report Form”) recounting the number and Net Sales (expressed in U. S. dollars) of all sales, leases, or other dispositions of Licensed Products, whether made by Company or a Sublicensee,
during such calendar quarter. Included in each sales report will be the name of each Distributor, and the number and type of Licensed Product sold, leased, or otherwise provided to such Distributor. Company shall deliver such written report to
University even if Company is not required hereunder to pay to University a payment for sales, leases, or other dispositions of Licensed Products during the calendar quarter. 

  

							
		  	 	Page 7 of 21	 	 	

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 6.5. Records Retention and Audit Rights. 

6.5.1. Records Retained. Throughout the term of this Agreement and for five (5) years thereafter, Company, at its
expense, shall keep and maintain and shall cause each Sublicensee to keep and maintain complete and accurate records of all sales, leases, and other dispositions of Licensed Products during the term of this Agreement and all other records
related to this Agreement. 
 6.5.2. Auditing Rights. Company shall permit, at the request of University, one or more
accountants selected exclusively by the University (“Accountants”) to have access to Company’s records and books of account pertaining to this Agreement. Accountants’ access will be during ordinary working hours to audit
Company’s records for any payment period ending prior to such request, the correctness of any report or payment made under this Agreement, or to obtain information as to the payments due for any period in the case of failure of Company to
report or make payment pursuant to the terms of this Agreement or to verify Company’s compliance with its payment obligations hereunder. Company shall cause each Sublicensee that manufactures, sells, leases, or otherwise disposes of Licensed
Products on behalf of Company to grant University the right to inspect and audit Sublicensee’s records. 
 6.5.3.
Scope of Disclosure. Accountants shall not disclose to University any information relating to the business of Company except that which is necessary to inform University of: the accuracy or inaccuracy of Company’s reports and payments;
compliance or noncompliance by Company with the terms and conditions of this Agreement; and the extent of any inaccuracy or noncompliance. 

6.5.4. Accountant Copies. If Accountants believe there is an inaccuracy in any of Company’s payments or
noncompliance by Company with any terms and conditions, Accountants shall have the right to make and retain copies (including photocopies) of any pertinent portions of the records and books of account. 

6.5.5. Costs of Audit. If Company’s royalties calculated for any calendar year quarterly period are under-reported
by more than 5%, the costs of any audit and review initiated by University will be borne by Company; otherwise, University shall bear the costs of any audit initiated by University. 

 

	7.	Infringement. 

 7.1. Third-Party Infringement of a Licensed Patent.  

7.1.1. Notice of Third Party’s Infringement. If a Party learns of substantial, credible evidence that a Third Party
is infringing a Licensed Patent in the Field of Use in the Territory, that Party will promptly deliver written notice of the possible infringement to the other Party, describing in detail all relevant information to which that Party has access or
control suggesting infringement of the Licensed Patent.  
 7.1.2. Company’s First Right to Settle. During
the term of this Agreement, Company has the first right to respond to, defend, and prosecute in its own name and at its own expense actions or suits relating to Licensed Patents. To enjoy said first right, Company must initiate bona fide action to
respond to any alleged infringement within 90 days of learning of said infringement. If required by law, University agrees to be joined as a party plaintiff; provided that Company must notify University at least ten (10) days before filing suit
and provided that Company shall reimburse University for all reasonable legal fees and costs incident thereto. Company shall not settle any suits or actions in any manner relating to the Licensed Patents without obtaining the prior written consent
of University. 

  

							
		  	 	Page 8 of 21	 	 	

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 7.1.2.1. Distribution of Proceeds from Settlement. Out of any proceeds from any
settlement for infringement of Licensed Patents, Company is allowed to first recover its reasonable attorney’s fees and other out-of-pocket expenses directly
related to any action, suit, or settlement for infringement of Licensed Patents. Any remaining proceeds will be distributed as follows: Company shall retain [XXX] and shall distribute [XXX] to University. Any payment by an alleged infringer that
constitutes consideration for Net Sales of infringing product, however, will be handled according to the payment provisions of Article 6 “Payments, Reimbursements, Reports, and Records” and Section A3.3 “Running Royalty Payments”
of Exhibit A “Exclusive Patent License Schedule”. Any payment by an alleged infringer that constitutes consideration for the grant of a Sublicense will be handled according to Section A3.7 “Sublicensing Consideration” of Exhibit
A “Exclusive Patent License Schedule”. 
 7.1.2.2. Limitation on Infringement Actions. Excluded from the rights granted
herein is the right to bring an infringement action against any inventor or their present or future not-for-profit employers, for infringement of the License Patents in
carrying out not-for-profit research. 

7.1.3. University Right to Institute Action. If Company fails, within 90 days of learning of an alleged infringement, to
secure cessation of the infringement, institute suit against the infringer, or to provide to University satisfactory evidence that Company is engaged in bona fide negotiations for the acceptance by infringer of a Sublicense in and to relevant
patents in Licensed Patents for the Field of Use, then University may, upon written notice to Company, assume full right and responsibility to secure cessation of the infringement, institute suit against the infringer, or secure acceptance of a
Sublicense by Company from the alleged infringer in and to relevant patents in Licensed Patents. Such license shall not be subject to Company’s approval. If University, in accordance with the terms and conditions of this Agreement, chooses to
institute suit against an alleged infringer, University may bring such suit in its own name (or, if required by law, in its and Company’s name) and at its own expense, and Company shall, but at University’s expense for Company’s
direct associated expenses, fully and promptly cooperate and assist University in connection with any such suit. All license fees, royalties, damages, awards, or settlement proceeds arising from such a University-initiated action will be solely for
the account of University. 
 7.1.4. No Obligation to Institute Action. Neither Company nor University is obligated
under this Agreement to institute or prosecute a suit against any alleged infringer of Licensed Patents. 
  

	8.	Patent Validity. 

 8.1. Notice and Investigation of Third Party Challenges. If any
Third Party challenges the validity or enforceability of any of the Licensed Patents, the Party having such information shall immediately notify the other Party. 

8.2. Tender to University of Third Party Actions. In the event of Third Party legal action challenging the validity or enforceability of
any of the Licensed Patents, University, at its sole discretion, shall have the right to assume and control the sole defense of the claim at University’s expense. If University opts not to assume and control the sole defense of the claim within
30 days after becoming 

  

							
		  	 	Page 9 of 21	 	 	

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
aware of challenge, Company shall have the right to assume the defense of the claim at its own expense. Company shall not settle any suits or actions in any manner relating to the Licensed
Patents without obtaining the prior written consent of University. 
 8.3. Enforceability of Licensed Patents. Notwithstanding
challenge by any Third Party, any Licensed Patent will be enforceable under this Agreement until such Licensed Patent is determined to be invalid. 
  

	9.	Termination. 

 9.1. By University. 

9.1.1. Breach by Company. If Company breaches or fails to perform one or more of its material duties under this
Agreement, University may deliver to Company a written notice of default. University may terminate this Agreement by delivering to Company a written notice of termination if the default has not cured in full within 60 days of the delivery to Company
of the notice of default. 
 9.1.2. Events of Default. University may terminate this Agreement by delivering to
Company a written notice of termination at least ten (10) days prior to the date of termination if Company (i) becomes insolvent; (ii) voluntarily files or has filed against it a petition under applicable bankruptcy or insolvency laws
that Company fails to have released within 30 days after filing; (iii) proposes any dissolution, composition, or financial reorganization with creditors or if a receiver, trustee, custodian, or similar agent is appointed; (iv) makes a
general assignment for the benefit of creditors; or (v) if Company challenges the validity of the Licensed Patents. 
 9.2. By
Company. Company may terminate this Agreement at any time by delivering to University a written notice of termination at least 60 days prior to the effective date of termination. 

9.3. Effect of Termination. 

9.3.1. License Terminated. After termination of this Agreement, Company shall not make, have made, use, offer to sell or
sell, offer to lease or lease, import, or otherwise offer to dispose or dispose of Licensed Products. 
 9.3.2. Final
Report to University. Within 60 days after the end of the calendar quarter following the expiration or termination of this Agreement, Company shall submit a final report to University. Any payments, including those incurred but not yet paid
(such as the pro-rata minimum annual royalty, and those related to patent expense incurred as of the date of termination but not yet paid), due to University shall become immediately due and payable upon
termination or expiration. 
 9.3.3. Termination of Sublicenses. Upon termination of this Agreement for any reason
prior to expiration, each Sublicense will terminate and Company will include a statement to that effect in each Sublicense. Company shall be liable for any costs, expenses, or damages payable to any Sublicensee arising out of the termination of a
Sublicense. At any time within 30 days following termination of this Agreement, a Sublicensee may notify University that it wishes to enter into a direct license with University in order to retain its rights to the Licensed Patents granted to it
under its Sublicense (such 30-day period following termination, the “Initial Notice Period”). Following 

  

							
		  	 	Page 10 of 21	 	 	

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
receipt of such notice, University and Sublicensee shall enter into a license agreement the terms of which shall be substantially similar to the terms of this Agreement; and the scope of such
direct license, the licensed territory or the duration of the license grant shall be comparable to the corresponding terms granted by the Company to such Sublicensee; provided that such Sublicensee will be granted at least the same scope of rights
as it obtained from Company under its Sublicense. For the sake of clarity, the financial terms, including without limitation, the running royalty rate and milestone payments, shall be identical to the corresponding financial terms set forth in this
Agreement. Notwithstanding the foregoing, each Sublicensee’s right to enter into such direct license shall be conditioned upon: 

9.3.3.1. Written Notification to University. Such Sublicensee informing University in writing, pursuant to Article 21
“Notices”, that it wishes to enter into such direct license with University, within the Initial Notice Period; 
 9.3.3.2.
Sublicensee Good Standing. Such Sublicensee being in good standing with Company under its Sublicense, and such Sublicense not being the subject of a dispute between Sublicensee and Company, or between Company and University under this
Agreement; 
 9.3.3.3. Valid Sublicense. Such Sublicense having been validly entered into by Company and Sublicensee pursuant to the
terms of Section 3.1.2 “Sublicenses”; 
 9.3.3.4. Sublicensee Certification that Conditions Satisfied. Such
Sublicensee using reasonable efforts to certify or otherwise demonstrate that the conditions set forth in subsections 9.3.3.1 “Written Notification to University”, 9.3.3.2 “Sublicensee Good Standing”, and 9.3.3.3 “Valid
Sublicense” have been met within 30 days of expiration of the Initial Notice Period (or within such longer period of time as University agrees is reasonable under the circumstances, based on the nature and extent of any documentation reasonably
requested by University); and 
 9.3.3.5. Time Limitations. Such negotiations for a direct license not exceeding 90 days from the end
of the 30-day (or longer, if applicable) period described in subsection 9.3.3.4 “Sublicensee Certification that Conditions Satisfied” (subject to extension of said
90-day period by mutual written agreement of University and Sublicensee). 

University may, at its sole discretion, waive any of these requirements. If all of the conditions set forth in this
Section 9.3.3 “Sublicenses” are met, then Sublicensee will be granted such direct license by University. If any condition set forth in this Section 9.3.3 “Sublicenses” is not met, then after expiration of any time
period granted to Sublicensee with respect to meeting such condition (for example and to the extent applicable, the Initial Notice Period and/or the periods described in subsections 9.3.3.4 “Sublicensee Certification that Conditions
Satisfied” and 9.3.3.5 “Time Limitations”), Sublicensee shall not make, have made, use, offer to sell or sell, offer to lease or lease, import, or otherwise offer to dispose or dispose of Licensed Products and University shall be free
to license or not license Licensed Patents to such Sublicensee according to its sole discretion. 

  

							
		  	 	Page 11 of 21	 	 	

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

	10.	Release, Indemnification, and Insurance. 

 10.1. Company’s Release. For
itself and its employees, Company hereby releases University and its regents, employees, and agents forever from any suits, actions, claims, liabilities, demands, damages, losses, or expenses (including reasonable attorneys’ and investigative
expenses) relating to or arising out of (i) the manufacture, use, lease, sale, or other disposition of a Licensed Product; or (ii) the assigning or sublicensing of Company’s rights under this Agreement. 

10.2. Company’s Indemnification. Throughout the term of this Agreement and thereafter, Company shall indemnify, defend, and hold
University and its regents, employees, and agents harmless from all suits, actions, claims, liabilities, demands, damages, losses, or expenses (including reasonable attorneys’ and investigative expenses), relating to or arising out of the
manufacture, use, lease, sale, or other disposition of a Licensed Product, including, without limitation, personal injury, property damage, breach of contract and warranty and products-liability claims relating to a Licensed Product and claims
brought by a Sublicensee. 
 10.3. Company’s Insurance. 

10.3.1. General Insurance Requirement. Throughout the term of this Agreement, or during such period as the Parties shall
agree in writing, Company shall maintain, and shall cause each Sublicensee to maintain, in full force and effect commercial general liability (CGL) insurance, with single claim limits consistent with industry standards. Such insurance policy will
include coverage for claims that may be asserted by University against Company under section 10.2 “Company’s Indemnification”. Such insurance policy must name the Board of Regents of the University of Washington as an additional
insured and will require the insurer to deliver written notice to University at the address set forth in Article 21 “Notices” of this Agreement, at least 45 days prior to the termination of the policy. Company shall deliver to University a
copy of the certificate of insurance for such policy. 
 10.3.2. Clinical Trial Liability Insurance. Within thirty
(30) days prior to the initiation of human clinical trials with respect to Licensed Product(s), Company shall provide to University certificates evidencing the existence and amount of clinical trials liability insurance. Company shall issue
irrevocable instructions to its insurance agent and to the issuing insurance company to notify University of any discontinuance or lapse of such insurance not less than 45 days prior to the time that any such discontinuance is due to become
effective. Company shall provide University a copy of such instructions upon their transmittal to the insurance agent and issuing insurance company. Company shall further provide University, at least annually, proof of continued coverage. 

 

	11.	Warranties. 

 11.1. Authority. Each Party represents and warrants to the other
Party that it has full corporate power and authority to execute, deliver, and perform this Agreement, and that no other corporate proceedings by such Party are necessary to authorize the Party’s execution or delivery of this Agreement. 

11.2. Disclaimers.  

11.2.1. General Disclaimers. EXCEPT FOR THE EXPRESS WARRANTY SET FORTH IN SECTION 11.1 “Authority” OF THIS
AGREEMENT, UNIVERSITY DISCLAIMS AND EXCLUDES ALL WARRANTIES, EXPRESS AND IMPLIED, CONCERNING EACH LICENSED PATENT AND EACH LICENSED PRODUCT, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF NON-INFRINGEMENT
AND THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. 

  

							
		  	 	Page 12 of 21	 	 	

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 11.2.2. Patent Disclaimers. University expressly disclaims any
warranties concerning and makes no representations: 
 11.2.2.1. Patent Issuance. That the Licensed Patent(s) will be approved or
will issue; 
 11.2.2.2. Licensed Patent Validity/Scope. Concerning the validity or scope of any Licensed Patent; or 

11.2.2.3. Non-Infringement. That the manufacture, use, sale, lease or other disposition of a
Licensed Product will not infringe a Third Party’s patent or violate a Third Party’s intellectual property rights. 
  

	12.	Damages. 

 12.1. Remedy Limitation. EVEN IF ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES, IN NO EVENT SHALL UNIVERSITY BE LIABLE FOR (A) PERSONAL INJURY OR PROPERTY DAMAGES ARISING IN CONNECTION WITH THE ACTIVITIES CONTEMPLATED IN THIS AGREEMENT OR (B) LOST PROFITS, LOST BUSINESS
OPPORTUNITY, INVENTORY LOSS, WORK STOPPAGE, LOST DATA OR ANY OTHER RELIANCE OR EXPECTANCY, INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES, OF ANY KIND. 

12.2. Damage Cap. IN NO EVENT WILL UNIVERSITY’S TOTAL LIABILITY FOR THE BREACH OR NONPERFORMANCE OF THIS AGREEMENT EXCEED THE
AMOUNT OF PAYMENTS PAID TO UNIVERSITY UNDER SECTION A3 “PAYMENTS” of Exhibit A “EXCLUSIVE PATENT LICENSE SCHEDULE” OF THIS AGREEMENT. THIS LIMITATION WILL APPLY TO CONTRACT, TORT, AND ANY OTHER CLAIM OF WHATEVER NATURE.  

 

	13.	Amendment and Waiver. 

 This Agreement may be amended from time to time only by a written
instrument signed by the Parties. No term or provision of this Agreement will be waived and no breach excused unless such waiver or consent will be in writing and signed by the Party claimed to have waived or consented. No waiver of a breach will be
deemed to be a waiver of a different or subsequent breach. 
  

	14.	Assignment. 

 The rights and licenses granted by University in this Agreement are
personal to Company and Company shall not assign its interest or delegate its duties under this Agreement without the written consent of University; any such assignment or delegation made without written consent of University will not release
Company from its obligations under this Agreement. The preceding sentence notwithstanding, Company, without the prior approval of University, may assign all, but no less than all, its rights and delegate all, but no less than all, its duties under
this Agreement to a Third Party provided that: 
  

	 	(i)	the assignment is made to such Third Party as a part of and in connection with (a) the sale by Company of all but no less than all of its assets to the Third Party, (b) if Company has more than one bona fide
drug development programs, the sale by Company of all but no less than all of the assets of its business most closely associated with this Agreement, to the Third Party, (c) the sale, transfer, or exchange by the shareholders, partners, or equity
owners of Company of a majority interest in Company to the Third Party, or (d) the merger of Company into the Third Party (each of the events described in part (a), (b), (c), or (d) of this paragraph, an “Assignment”).

  

							
		  	 	Page 13 of 21	 	 	

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

	 	(ii)	Company obtains from such Third Party written agreement to honor all obligations under this Agreement accrued by Company before Assignment and all obligations under this Agreement to accrue by such Third Party assignee
after Assignment, including any and all financial obligations, and 

  

	 	(iii)	no later than ten (10) days after the close of the transaction pursuant to which such Assignment is made, Company shall provide written notice to University of the Assignment, as well as a substitution of parties
document, in which such Third Party assignee assumes responsibility for all of Company’s outstanding and future obligations relating to this Agreement. Any assignment made in violation of this Article will be void and will, without further act,
cause the immediate termination of this Agreement, effective retroactively to the date of the Assignment. 

 This Agreement will inure to the
benefit of Company and University and their respective permitted assignees and trustees. 
  

	15.	Confidentiality. 

 15.1. Form of transfer. Confidential Information may be
conveyed in tangible or intangible form. Disclosing Party must clearly mark its Confidential Information “confidential.” If disclosing Party communicates Confidential Information in non-written form,
it shall reduce such communications to writing, clearly mark it “confidential”, and provide a copy to receiving Party within 30 days of original communication at the address in Article 21 “Notices”. 

15.2. No Unauthorized Disclosure of Confidential Information. Beginning on the Effective Date and continuing throughout the term of
this Agreement and thereafter for a period of [XXX], receiving Party shall not disclose or otherwise make known or available to any Third Party any disclosing Party Confidential Information, without the express prior written consent of disclosing
Party. Notwithstanding the foregoing, receiving Party shall be permitted to disclose disclosing Party Confidential Information to (i) actual or potential investors, lenders, consultants, collaborators, Sublicensees, or development partners,
which disclosure will be made under conditions of confidentiality and limited use and (ii) its attorney or agent as reasonably required. In no event shall receiving Party incorporate or otherwise use disclosing Party’s Confidential
Information in connection with any patent application filed by or on behalf of receiving Party. Receiving Party shall restrict the use of disclosing Party’s Confidential Information exclusively to the terms of this Agreement. Receiving Party
shall use reasonable procedures to safeguard disclosing Party’s Confidential Information. In the case where Company is the receiving Party, Company’s confidentiality obligations will also apply equally to Sublicensees.  

15.3. Access to University Information. University is an agency of the state of Washington and is subject to the Washington
Public Records Act, RCW 42.56 et seq., (“Act”), and no obligation assumed by University under this Agreement shall be deemed to be inconsistent with University’s obligations as defined under the Act and as interpreted by University in
its sole discretion. If University receives a request for public records under the Act for documents containing Company Confidential Information, and if University concludes that the documents are not otherwise exempt from public disclosure,
University will provide Company notice of the request before releasing such documents. Such notice 

  

							
		  	 	Page 14 of 21	 	 	

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
will be provided in a timely manner to afford Company sufficient time to review such documents and/or seek a protective order, at Company’s expense utilizing the procedures described in RCW
42.56.540. University shall have no obligation to protect Company Confidential Information from disclosure in response to a request for public records. 

15.4. Disclosure as Required by Law. Either Party shall have the right to disclose the other Party’s Confidential Information as
required by law or valid court order, provided that such Party shall inform the Party who owns such Confidential Information prior to such disclosure and shall limit the scope and recipient of disclosure to the extent required by such law or court
order. 
  

	16.	Consent and Approvals. 

 Except as otherwise expressly provided, all consents or
approvals required under the terms of this Agreement must be in writing and will not be unreasonably withheld or delayed. 
  

	17.	Construction. 

 The headings preceding and labeling the sections of this Agreement are
for the purpose of identification only and will not in any event be employed or used for the purpose of construction or interpretation of any portion of this Agreement. As used herein and where necessary, the singular includes the plural and vice
versa, and masculine, feminine, and neuter expressions are interchangeable. 
  

	18.	Enforceability. 

 If a court of competent jurisdiction adjudges a provision of this
Agreement unenforceable, invalid, or void, such determination will not impair the enforceability of any of the remaining provisions hereof and the provisions will remain in full force and effect. 

 

	19.	No Third-Party Beneficiaries. 

 No provision of this Agreement, express or implied,
confers upon any person other than the Parties to this Agreement any rights, remedies, obligations, or liabilities hereunder. No Sublicensee shall have a right to enforce or seek damages under this Agreement. 

 

	20.	Language. 

 Unless otherwise expressly provided in this Agreement, all notices, reports,
and other documents and instruments that a Party hereto elects or is required by the terms of this Agreement to deliver to the other Party hereto will be in English. 

  

							
		  	 	Page 15 of 21	 	 	

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

	21.	Notices. 

 All notices, requests, and other communications that a Party is required or
elects to deliver will be in writing and will be delivered personally, or by facsimile or electronic mail (provided such delivery is confirmed), or by a recognized overnight courier service or by United States mail, first-class, certified or
registered, postage prepaid, return receipt requested, to the other Party at its address set forth below or to another address as a Party may designate by notice given pursuant to this article: 

 

			
	If to University:	  	UW CoMotion
		  	ATTN: Director, Innovation Development
		  	4311 11th Avenue NE, Suite 500
		  	Seattle, WA 98105-4608
		  	Facsimile No.:
		
	If to Company:	  	Attn: Charles Legg, Head of Program Management
		  	Solid GT
		  	One Broadway
		  	Cambridge, MA 02142
		  	E-mail:

  

	22.	Patent Marking. 

 Company shall mark all material forms of Licensed Product(s) or
packaging pertaining thereto made and sold by Company in the United States with patent marking conforming to 35 U.S.C. §287(a), as amended from time to time. Such marking shall further identify the pendency of any U.S. patent application and/or
any issued U.S. or foreign patent forming any part of the Licensed Patents. All Licensed Product(s) shipped to or sold in other countries will be marked in such a manner as to provide notice to potential infringers pursuant to the patent law and
practice of the country of manufacture or sale. 
  

	23.	Publicity. 

 University shall have the right to report in its customary publications and
presentations that University and Company have entered into a license agreement for the technology covered by the Licensed Patents and University may use Company logos in such publications and presentations provided that University does not modify
Company’s logos and does not through such use imply any endorsement by Company of University.     
 The Parties
will cooperate with one another to review and respond to any press release or similar communication proposed by the other Party regarding the non-confidential subject matter of this Agreement. The specific
content and timing of such press releases or similar communication is subject to mutual agreement by the Parties, which will not be unreasonably withheld. Further, University and Company shall issue a joint press release regarding this Agreement,
subject to both Party’s review and approval of the specific content thereof, and such press release shall include specific mention of the contributions of University personnel and University in developing the technology in a prominent portion
of the press release. Company shall provide University with appropriate quotes for such press release. University may post the press release in digital and print publications as well as on University’s own website. 

 

	24.	Relationship of Parties. 

 In entering into, and performing their duties under, this
Agreement, the Parties are acting as independent contractors and independent employers. No provision of this Agreement shall create or be construed as creating a partnership, joint venture, or agency relationship between the Parties. No Party shall
have the authority to act for or bind the other Party in any respect. 

  

							
		  	 	Page 16 of 21	 	 	

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

	25.	Relationship with Principal Investigator. 

 Company acknowledges that Principal
Investigator is employed by University and has certain pre-existing obligations to University, including obligations with respect to disclosure and ownership of intellectual property and obligations arising
from sponsored research agreements between University and Third Parties. Accordingly, Company agrees that to the extent that any consulting agreement is inconsistent with any of Principal Investigator’s obligations to University, including the
reporting of all inventions developed while employed by University (regardless of where arising) and including contractual obligations arising under any sponsored research agreements between University and Third Parties, then Principal
Investigator’s obligations to University shall prevail and to such extent any inconsistent provisions of this consulting agreement shall be deemed inapplicable and unenforceable. 

 

	26.	Security Interest. 

 In no event shall Company grant, or permit any person to assert or
perfect, a security interest in Licensed Patents or in Company’s rights under this Agreement. 
  

	27.	Survival. 

 Immediately upon the termination or expiration of this Agreement all
Company’s rights under this Agreement will terminate; provided, however, Company’s obligations that have accrued prior to the effective date of termination or expiration of this Agreement (e.g., the obligation to report and make
payments on sales, leases, or dispositions of Licensed Products and to reimburse University for costs) and the obligations specified in Sections 6.1 “Payments” and 6.4 “Sales Reports” will survive. The obligations and rights set
forth in Sections 6.5 “Records Retention and Audit Rights” and 9.3 “Effect of Termination” and Articles 10 “Release, Indemnification, and Insurance”, 11 “Warranties”, 12 “Damages”, 15
“Confidentiality”, 29 “Applicable Law” and 30 “Forum Selection” will survive the termination or expiration of this Agreement. 
  

	28.	Collection Costs and Attorneys’ Fees. 

 If a Party fails to perform an obligation or
otherwise breaches one or more of the terms of this Agreement, the other Party may recover from the non-performing breaching Party all its costs (including actual attorneys’ and investigative fees) to
enforce the terms of this Agreement. 
  

	29.	Applicable Law. 

 The internal laws of the state of Washington will govern the validity,
construction, and enforceability of this Agreement, without giving effect to the conflict of laws principles thereof. 
  

	30.	Forum Selection. 

 A suit, claim, or other action to enforce the terms of this Agreement
will be brought exclusively in the state and federal courts of King County, Washington. Company hereby submits to the jurisdiction of that court and waives any objections it may have to that court asserting jurisdiction over Company or its assets
and property. 
  

	31.	Entire Agreement. 

 Company has evaluated the Licensed Patents under a Confidentiality
Agreement (“CDA”) with University (UW # 35111A) with an effective date of June 16th, 2014 and under an Exclusive Option 

  

							
		  	 	Page 17 of 21	 	 	

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
(“Option”) with University (UW # 36201A) with an effective date of February 5th, 2015. This Agreement (including all attachments,
exhibits, and amendments) is the final and complete understanding between the Parties concerning licensing the Licensed Patents. This Agreement supersedes any and all prior or contemporaneous negotiations, representations, and agreements, whether
written or oral, concerning the Licensed Patents. However, the obligations of nonuse and nondisclosure for Confidential Information disclosed pursuant to the CDA shall survive until June 16, 2019. Confidential Information disclosed pursuant to
this Agreement shall be governed by the terms of this Agreement. This Agreement may not be modified in any manner, except by written agreement signed by an authorized representative of both Parties. 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed by their respective authorized representatives. 

 

							
	University of Washington	  	Solid GT	 	
				
	By:	  	 /s/ Fiona Wills
	  	By:	 	 /s/ Ilan Ganot

				
	Name:	  	 Fiona Wills
	  	Name:	 	 Ilan Ganot

				
	Title:	  	 Director, Innovation Development
	  	Title:	 	 CEO

				
	Date:	  	 10/16/2015
	  	Date:	 	 10/16/2015

  

							
		  	 	Page 18 of 21	 	 	

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 Exhibit A 

Exclusive Patent License Schedule 
 A1.
Licensed Patents: 
  

									
	 UW Reference #
	 	 Application Serial #
	 	 Filing Date
	 	 Type
	 	 Status

	 [XXX]
	 	 [XXX]
	 	[XXX]	 	[XXX]	 	[XXX]

 A2. Performance Milestones (Section 5.1 “Commercialization and Performance Milestones”): 

Company shall meet the following performance milestones: 

A2.1 Milestone 1 – [XXX] 

A2.2 Milestone 2- [XXX] 

A2.3 Milestone 3 – [XXX] 

A2.4 Milestone 4 – [XXX] 
 A3. Payments
(Section 6.1): 
 A3.1 Up-front Payment. Company shall pay to University within 14 days of
the Effective Date [XXX] as an up-front payment. This up-front payment shall be non-refundable and not creditable against future
royalty obligations. 
 A3.2 Annual Maintenance Fee. Company shall pay to University an annual maintenance fee of [XXX] due on the
2nd anniversary of the Effective Date and every year thereafter for the term of the Agreement. Annual Maintenance Fees shall terminate immediately when Company begins to pay Minimum Annual Royalties (A3.4). 

A3.3 Running Royalty Payments. Company shall pay to University within 30 days after the last day of each calendar quarter during the
term of this Agreement an amount equal to [XXX] of Net Sales during such quarter as a running royalty payment. 
 A3.4 Minimum Annual
Royalties. Company as well as each of its Sublicensees shall pay minimum annual royalties of [XXX] for the term of this Agreement to be creditable against running royalty payments for the preceding calendar year on a non-cumulative basis and to be due in full and payable on January 31st of each year beginning on January 31st of the second year following the first commercial sale and continuing during the term of this
Agreement. 
 A3.4.1. If this Agreement is terminated prior to the payment of a minimum annual royalty in any given year the amount due for
that minimum annual royalty payment will be prorated on the basis of the number of full quarters that have elapsed prior to termination since the last payment of a minimum annual royalty. 

  

							
		  	 	Page 19 of 21	 	 	

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 A3.5 Financial Milestones. Company shall pay to University the following non-cumulative and non-refundable milestone achievement payments within 30 days of achieving the corresponding milestone, whether achieved by Company or a Sublicensee. For
clarity, payments will be due only once in respect of the first achievement of the milestones below for a Licensed Product, regardless of the number of Licensed Products to achieve the milestone. 

A3.5.2. [XXX] 
 A3.5.3. [XXX] 

A3.5.4. [XXX] 
 A3.5.5. [XXX] 

A3.6 Third Party Royalties. If Company is required to pay royalties to a Third Party based on Company’s manufacture, use, or sale
of Licensed Product subject to one or more patents of such Third Party then the royalty Company pays to University may be reduced by [XXX] of the royalty actually paid to the Third Party provided that use of any Third Party patent is required for
such manufacture, use, or sale of Licensed Product, and provided that the royalty to the University shall not fall below [XXX]. 
 A3.7
Sublicensing Consideration. Within 30 days of the end of each calendar quarter during the term of this Agreement, Company shall pay to University [XXX] of any Sublicensing Consideration received by Company during such calendar quarter unless
reduced by achievement of milestones by Company or its Sublicensee prior to execution of the particular Sublicense in accordance with the schedule below. A reduction of the percentage of Sublicensing Consideration payable to University under this
Agreement will be negotiated in good faith between the Parties where, in addition to the Sublicense of any rights granted to Company hereunder, Company also grants Sublicensee a license under a Third Party’s intellectual property rights, which
license is necessary for Sublicensee to manufacture, have manufactured, use, offer to sell or sell, offer to lease or lease, import, or otherwise offer to dispose or dispose of Licensed Product(s) without infringing such Third Party’s
intellectual property rights, and only to the extent that the total aggregate consideration for such combined license is treated as Sublicensing Consideration. 

A3.7.1. After achievement of Milestone 1: [XXX] 

A3.7.2. After achievement of Milestone 2: [XXX] 

A3.7.3. After achievement of Milestone 3: [XXX] 

A3.8 Assignment Fee. Within 30 days of any assignment of rights granted to Company under this Agreement, Company shall pay to
University [XXX] of any Assignment Consideration received by Company. 
 A4. Patent Cost Reimbursement: Company shall reimburse University for
all Patent Expenses incurred prior to the Effective Date within 60 days of the Effective Date. Company shall pay, or reimburse University for paying, all Patent Expenses incurred on or after the Effective Date within 30 days of its receipt of
University’s invoice for such Patent Expenses. University reserves the right to request advance payments for certain Patent Expenses, at University’s discretion. 

  

							
		  	 	Page 20 of 21	 	 	

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 Exhibit B 

Royalty Report Form 
 Date 

Company Name & Address 
  

							
	 License Number
	  	
                  
                   
	  		  	

  

									
	 Reporting Period: 
	  	 	 	Report Due Date: 	  	 	  	

  

							
	This report must be submitted regardless of whether royalties are owed.	  	
		
	Please do not leave any column blank. State all information requested below.	  	
				
	 Product Description
	  	 Royalty Rate
	  	 Quantity/

Net Sales
	  	 Royalty Due

		  		  		  	
		  		  		  	
		  		  		  	
		  		  		  	
		  		  		  	

  

									
	 Report Completed by:
	 	  
	 		 	 Total Royalties Due:
	 	  

							
				
	 Telephone Number:
	 	  
	 		 	

							
			
	 If you have questions please contact:
                                        

	 		 	

 Please make check payable to: University of Washington 

  

							
		  	 	Page 21 of 21	 	 	

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.EX-10.11

 Exhibit 10.11 

CONFIDENTIAL TREATMENT REQUESTED 
 PATENT
LICENSE AGREEMENT 
 This Agreement is effective as of March 10, 2016 (the “EFFECTIVE DATE”), between Solid GT, LLC (“LICENSEE”)
having the address in Article 12 below, and the Regents of the University of Michigan, a constitutional corporation of the state of Michigan (“MICHIGAN”) having the address in Article 12 below. LICENSEE and MICHIGAN hereby agree as
follows: 
 ARTICLE 1 – DEFINITIONS 

“AFFILIATE” means any corporation, partnership, joint venture or other entity of which a majority of the voting stock or other equity ownership
thereof is owned or controlled by, or under common control with, LICENSEE, or which owns or controls a majority of the voting stock or other equity ownership of LICENSEE. 

“FIELD OF USE” means all uses. 
 “FIRST
COMMERCIAL SALE” means the first SALE through a bona fide arms length transaction of any LICENSED PRODUCT or first commercial use of any LICENSED PROCESS by LICENSEE or a SUBLICENSEE, excluding the SALE of a LICENSED PRODUCT or use of a
LICENSED PROCESS for use in trials, as a sample or that is of temporary availability. 
 “LICENSED PROCESS(ES)” means any process or method that,
but for this Agreement, would comprises an infringement of (including contributory or inducement) a VALID CLAIM in the country in which any such process or method is used or performed, or (b) employs a LICENSED PRODUCT. 

“LICENSED PRODUCT(S)” means any product that: (a) but for this Agreement, comprises an infringement of (including contributory or inducement) a
VALID CLAIM in the country in which any such product or product part is made, used, imported, offered for SALE or sold; or (b) is manufactured by using a LICENSED PROCESS or is employed to practice a LICENSED PROCESS. 

“MICHIGAN,” as used in Articles 9 and 10, shall include its Regents, officers, employees, students, and agents. 

“NET SALES” means the amount billed or invoiced, and if any amount is not billed or invoiced, the amounts actually received, on Sales, however
characterized, by LICENSEE and/or SUBLICENSEES of LICENSED PRODUCTS and uses of LICENSED PROCESSES, less the following deductions (but only to the extent such deductions are otherwise included in NET SALES and are not obtained in view of other
consideration received by LICENSEE): 
 (a) cash discounts actually granted to customers in such invoices for SALE of LICENSED PRODUCTS, but
only in amounts customary in the trade; 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 (b) sales taxes, tariff duties and/or use taxes separately stated in such bills or invoices
with reference to particular SALES and actually paid by LICENSEE or SUBLICENSEE to a governmental unit; 
 (c) actual freight expenses
between LICENSEE or SUBLICENSEE and customers, to the extent such expenses are not charged to or reimbursed by customers; or 
 (d) amounts
actually refunded or credited on returns. 
 Where LICENSEE or SUBLICENSEE receives any consideration other than cash for such transactions,
fair market cash value for such consideration, to be agreed upon by the parties hereto, shall be included in NET SALES. Where a product or activity is a LICENSED PRODUCT or LICENSED PROCESS hereunder due to contributory infringement or inducement of
infringement, NET SALES shall include SALES of the product or process that constitutes a direct infringement of the PATENT RIGHTS. NET SALES shall not include LICENSED PRODUCT used for pre-clinical or clinical
trials, post-marketing trials, samples and indigent patient programs or any other uses of LICENSED PRODUCT not ordinarily included as part of NET SALES for royalty determination purposes. 

A sale or transfer to an AFFILIATE or SUBLICENSEE for re-sale by such AFFILIATE or SUBLICENSEE shall
not be considered a sale for the purpose of this provision but the resale by such AFFILIATE or SUBLICENSEE shall be a sale for such purposes. Any amounts received LICENSEE, an AFFILIATE or SUBLICENSEE in exchange for LICENSED PRODUCTS or LICENSED
PROCESSES transferred or provided to any person or entity for use in testing, clinical trials, or as marketing samples to develop or promote the LICENSED PRODUCTS are not included in the definition of NET SALES. 

“PATENT RIGHTS” means MICHIGAN’S legal rights under the patent laws of the United States or relevant foreign countries for all of the
following: 
 (a) the following United States and foreign patent(s) and/or patent application(s), and divisionals, continuations, continuations-in-part (only to the extent that such claims are fully supported under U.S. patent laws by another patent or application in the PATENT RIGHTS), and foreign
counterparts of the same: 
 [XXX]; and 

[XXX]; and 
 (b) any renewals,
reexaminations, substitutes, supplementary protection certificates and extensions of these patents, and any corresponding foreign counterparts of the same. 

“ROYALTY PERIOD(S)” means the six-month periods ending on the last days of June and December each year. 

  
 2 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 “SALE” means sale, rental, or lease, however characterized, and SOLD means the past tense of SALE.

 “SUBLICENSEE(S)” means any person or entity in writing sublicensed, or granted an option for a sublicense, by LICENSEE under this Agreement.

 “TERRITORY” means all of the countries of the world. 

“VALID CLAIM” means (i) a claim in an issued and unexpired patent included in the PATENT RIGHTS that: (a) has not been held unenforceable,
unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction, and not subject to appeal, (b) has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise,
(c) has not been lost through an interference, reexamination, or reissue proceeding; or (ii) a pending claim of a pending patent application included in the PATENT RIGHTS that has not been abandoned or finally rejected without the
possibility of appeal or refiling and that has been pending for less than seven years from its priority date. 
 ARTICLE 2 – GRANT OF
LICENSE 
 2.1 MICHIGAN hereby grants to LICENSEE an exclusive license under the PATENT RIGHTS, with the right to grant sublicenses, both subject to the
terms and conditions of this Agreement, in the FIELD OF USE and the TERRITORY to make, have made, import, use, market, offer for sale and sell LICENSED PRODUCTS and to practice LICENSED PROCESSES. 

2.2 Without limiting any other rights it may have, MICHIGAN specifically reserves the right for it and its affiliates to practice and have practiced the
PATENT RIGHTS for non-commercial research, public service, internal (including clinical) and/or educational purposes, and the right to grant the same limited
non-commercial rights to other non-profit research institutions. For avoidance of doubt, sponsored research on behalf of
for-profit entities shall be deemed to be commercial. 
 2.3 This Agreement shall extend until expiration of the
last to expire of the PATENT RIGHTS, unless sooner terminated as provided in another specific provision of this Agreement. 
 2.4 LICENSEE agrees that
LICENSED PRODUCTS used, leased or sold in the United States shall be manufactured substantially in the United States. 
 2.5 The licenses granted in this
Agreement are subject to any rights required to be granted under prior research or sponsorship agreements, or retained by the U.S. government, for example in accordance with Chapter 18 of Title 35 of U.S.C.
200-212 and the regulations thereunder (37 CFR Part 401), when applicable. LICENSEE agrees to comply in all respects, and shall provide MICHIGAN with all reasonably requested information and cooperation for
MICHIGAN to comply with applicable provisions of the same and any requirements of any agreements between MICHIGAN and any agency of the U.S. government that provided funding for the subject matter covered by the PATENT RIGHTS. 

  
 3 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 ARTICLE 3 - CONSIDERATION 

3.1 LICENSEE shall pay the following to MICHIGAN: 

(a) License Issue Fee. A License Issue Fee equal to [XXX], due within fourteen (14) days from the complete execution of this
Agreement. 
 (b) Annual Maintenance Fee. An Annual Maintenance Fee equal to [XXX], due within fourteen (14) days of the second
(2nd) anniversary of the EFFECTIVE DATE, and within fourteen (14) days of each subsequent anniversary of the EFFECTIVE DATE. The Annual Maintenance Fee shall not be due in any calendar year
that the LICENSEE pays Minimum Annual Royalties as described in Section 3.1 (e) or Running Royalties as described in Section 3.1 (b) in an amount equal to or greater than Minimum Annual Royalties. 

(b) Running Royalties. Running Royalties equal to [XXX] of NET SALES. If LICENSEE makes any SALES to any AFFILIATE at a price less than
the regular price charged to other parties, the Running Royalties payable to MICHIGAN shall be computed on the basis of the regular price charged to other parties. 

(c) Sublicensing Fees. Sublicensing Fees equal to a percentage of any revenue not based on product sales that LICENSEE or SUBLICENSEES
(or a designee) is due from or receives from SUBLICENSEES or assignees in consideration for rights under or relating to the PATENT RIGHTS (e.g., license issue fees, maintenance or annual minimum fees, milestone payments, other royalties), but
excluding, (a) amounts received for the purchase of securities; (b) payments of loans or other debt obligations, (c) payments made as a reimbursement of costs incurred, such as for patent prosecution costs, (d) amounts received
to cover research and development activities related to actual or potential LICENSED PRODUCTS or LICENSED PROCESSES after the effective date of the sublicense agreement, and (e) amounts attributable to intellectual property other than the
LICENSED PATENTS, as follows: 
  

	 	1)	[XXX] if the sublicense is entered into on or after the EFFECTIVE DATE and before [XXX]; 

  

	 	2)	[XXX] if the sublicense is entered into at or after [XXX] and before [XXX]; and 

  

	 	3)	[XXX] if [XXX] into at or after [XXX]. 

 (d) Back Patent Costs. Within fourteen
(14) days from complete execution of this Agreement, LICENSEE shall pay MICHIGAN all of the Back Patent Costs which are [XXX] as of March 10, 2016. 

  
 4 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 (e) Minimum Annual Royalties. Beginning with the FIRST COMMERCIAL SALE, Minimum Annual
Royalties are due for each calendar year within sixty (60) days following the end thereof. Minimum Annual Royalties shall be credited against Running Royalties (and, if paid first, Running Royalties shall be credited against Minimum Annual
Royalties) due on NET SALES made during the calendar year for which the Minimum Annual Royalties apply. Minimum Annual Royalties paid in excess of Running Royalties shall not be creditable to amounts due for future years. The Minimum Annual Royalty
is [XXX]. 
 (f) Milestone Payments for LICENSED PRODUCT as follows (for the avoidance of doubt, none of these Milestone Payments
shall be required to be paid more than once): 
 (a) [XXX] 

(b) [XXX] 
 (c) [XXX] 

(d) [XXX] 
 Milestone payments are non refundable
and non-creditable against royalties. 
 (g) Change of Control. [XXX] 

3.2 LICENSEE is not obligated to pay multiple royalties if any LICENSED PRODUCT or LICENSED PROCESS is covered by more than one VALID CLAIM or the same
LICENSED PRODUCT is covered by VALID CLAIMS in two or more countries. If LICENSEE or its AFFILIATES or SUBLICENSEE enters into a license agreement with a third party that LICENSEE reasonably determines is necessary and procured for the
commercialization of a LICENSED PRODUCT or LICENSED PROCESS and according to such license agreement a royalty must be paid to the third party by LICENSEE or its AFFILIATE or SUBLICENSEE based upon commercialization of a LICENSED PRODUCT or LICENSED
PROCESS, then the royalty otherwise payable to MICHIGAN pursuant to Section 3.1 may be reduced by [XXX] of the applicable third party royalty; provided that, in no instance shall the royalty payable to MICHIGAN by LICENSEE ever be reduced below
[XXX] of the otherwise applicable royalty. 

  
 5 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 3.3 Royalty payments shall be made to “The Regents of the University of Michigan” in United States
dollars. Payments drawn directly on a U.S. bank may be made by either check to the address in Article 12 or by wire transfer. Any payment drawn on a foreign bank or foreign branch of a U.S. bank shall be made only by wire transfer. Wire transfers
shall be made in accordance with the following or any other instructions as may be specified by MICHIGAN. In computing royalties, LICENSEE shall convert any revenues it receives in foreign currency into its equivalent in United States dollars at the
most recent exchange rate published in the Wall Street Journal on the last business day of the ROYALTY PERIOD during which such payments are received by LICENSEE, or at such other exchange rate as the parties may agree to in writing. 

3.4 Royalty payments shall be made on a semi-annual basis with submission of the reports required by Article 4. All amounts due under this Agreement,
including amounts due for the payment of patent expenses, shall, if overdue, be subject to a charge of interest [XXX] until payment, [XXX] above the prime rate in effect at the JP Morgan Chase Bank, N.A. or its successor bank on the due date (or at
the highest allowed rate if a lower rate is required by law) or [XXX], whichever is greater. The payment of such interest shall not foreclose MICHIGAN from exercising any other rights it may have resulting from any late payment. LICENSEE shall
reimburse MICHIGAN for the costs, including reasonable attorney fees, for expenses paid in order to collect any amounts overdue more than 120 days. 
 3.5
All payments made under this Agreement are and shall be non-refundable. MICHIGAN shall have no obligation whatsoever to pay, return, credit, or refund any amounts paid hereunder, except as may be specifically
provided herein. By way of example only, notwithstanding the deductions permitted to NET SALES, MICHIGAN shall have no obligation to pay any amounts to LICENSEE even if such deductions should result in a negative amount for NET SALES in any given
ROYALTY PERIOD. 
 3.6 The payments required to be paid by LICENSEE to MICHIGAN pursuant to this agreement may be paid with deduction for taxes withheld
under the LICENSEE’s or, if applicable, its SUBLICENSEE’s applicable domestic law. LICENSEE will reasonably assist MICHIGAN to obtain full benefit of any applicable tax treaty to reduce the amount of such withheld taxes. MICHIGAN shall be
responsible for the payment of all taxes, duties, levies, and other charges imposed by any taxing authority with respect to the royalties payable to MICHIGAN under this agreement. LICENSEE may withhold or deduct any portion of the payments due to
MICHIGAN required under applicable law or regulation of any government entity or authority. LICENSEE shall cooperate reasonably with MICHIGAN in the event MICHIGAN elects to assert, at its own expense, any exemption from any such tax or deduction.

 ARTICLE 4 - REPORTS 
 4.1 Until the
FIRST COMMERCIAL SALE, by July 31 of each year LICENSEE shall provide to MICHIGAN a written annual report that includes reports on progress since the prior annual report and general future plans regarding: research and development, regulatory
approvals, manufacturing, sublicensing, marketing and SALES. Further, LICENSEE shall 

  
 6 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
specifically report to MICHIGAN the FIRST COMMERCIAL SALE within sixty (60) days thereafter, and provide a brief description of the products or services subject of the FIRST COMMERCIAL SALE,
and terms thereof. 
 4.2 After the FIRST COMMERCIAL SALE, LICENSEE shall provide semi-annual reports to MICHIGAN. Specifically, as of the end of each
ROYALTY PERIOD (and delivered within sixty (60) days after such ROYALTY PERIOD closes, including the close of the ROYALTY PERIOD immediately following any termination of this Agreement), LICENSEE shall report to MICHIGAN for the applicable
ROYALTY PERIOD: 
 (a) number of LICENSED PRODUCTS sold, leased, or distributed, however characterized, by LICENSEE and each SUBLICENSEE.

 (b) NET SALES, excluding the deductions provided therefor, of LICENSED PRODUCTS SOLD by LICENSEE and all SUBLICENSEES. 

(c) a description and accounting for all LICENSED PROCESSES SOLD, by LICENSEE and all SUBLICENSEES included in NET SALES, excluding the
deductions therefor. 
 (d) deductions applicable as provided in the definition for NET SALES above, and an explanation of the rationale(s)
therefor. 
 (e) Sublicense Fees due on payments from SUBLICENSEES under Paragraph 3.1 above, including supporting figures. 

(f) foreign currency conversion rate and calculations (if applicable) and total royalties due. 

(g) each milestone under Article 3 or Article 5 having a deadline during the ROYALTY PERIOD, and a specific identification of whether or not it
was achieved. 
 (h) for each sublicense or amendment thereto completed in the particular ROYALTY PERIOD (including agreements under which
LICENSEE will have LICENSED PRODUCTS made by a third party): names, addresses, and U.S.P.T.O. Entity Status (as discussed in Paragraph 4.5) of such SUBLICENSEE; the date of each agreement and amendment; the territory of the sublicense; the scope of
the sublicense; and the nature, timing and amounts of all fees, royalties to be paid thereunder. 
 (i) progress on research and development,
regulatory approvals, manufacturing, sublicensing, marketing and SALES, and general plans for the future. 
 (j) the date of first SALE of
LICENSED PRODUCTS (or results of LICENSED PROCESSES) in each country and the circumstances thereof. 
 LICENSEE shall include the amount of all payments
due, and the various calculations used to arrive at those amounts, including the quantity, description (nomenclature and type designation as described in Paragraph 4.3 below), country of manufacture and country of SALE or use of LICENSED PRODUCTS
and LICENSED PROCESSES. 

  
 7 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 If no payment is due, LICENSEE shall so report to MICHIGAN that no payment is due. Failure to provide reports
as required under this Article 4 shall be a material breach of this Agreement. LICENSEE agrees to reasonably cooperate with MICHIGAN regarding any questions it may have relating to compliance with this Agreement, for example to discuss the
information in reports. 
 4.3 LICENSEE shall promptly establish and consistently employ a system of specific nomenclature and type designations for
LICENSED PRODUCTS and LICENSED PROCESSES to permit identification and segregation of various types where necessary, and shall require the same of SUBLICENSEES. 

4.4 LICENSEE shall keep, and shall require SUBLICENSEES to keep, true and accurate records containing data reasonably required for the computation and
verification of payments due under this Agreement. LICENSEE shall and it shall require all SUBLICENSEES and those making LICENSED PRODUCTS to: (a) open such records for inspection upon reasonable notice during business hours, and no more than
once per year, at MICHIGAN’s sole expense, by either MICHIGAN auditor(s) or an independent certified accountant selected by MICHIGAN and reasonably acceptable to LICENSEE, for the purpose of verifying the amount of payments due, and shall
provide information to MICHIGAN to facilitate such inspection; and (b) retain such records for six (6) years from date of origination. 
 The
terms of this Article shall survive any termination of this Agreement. MICHIGAN is responsible for all expenses of such inspection, except that if any inspection reveals an underpayment greater than [XXX] of royalties due MICHIGAN, then LICENSEE
shall pay all expenses of that inspection and the amount of the underpayment and interest to MICHIGAN within thirty (30) days of written notice thereof. LICENSEE shall also reimburse MICHIGAN for reasonable expenses required to collect the
amount underpaid. 
 4.5 So that MICHIGAN may pay the proper U.S. Patent and Trademark Office fees relating to the PATENT RIGHTS, if LICENSEE, any
AFFILIATE, or any SUBLICENSEE (including optionees) does not quality as a “Small Entity” under U.S. patent laws, LICENSEE shall notify MICHIGAN immediately. The parties understand that the changes to LICENSEE’s, AFFILIATE’s,
SUBLICENSEE’s, or optionees’ businesses that might affect entity status include: acquisitions, mergers, hiring of a total of more than 500 total employees, sublicense agreements, and sublicense options. 

ARTICLE 5 - DILIGENCE 
 5.1 LICENSEE shall
use commercially reasonable efforts to bring one or more LICENSED PRODUCTS to market, and/or one or more LICENSED PROCESSES to commercial use, through a diligent program for utilizing the PATENT RIGHTS and to continue diligent marketing efforts
throughout the life of this Agreement, in each case consistent with prudent business practices and judgment. LICENSEE has the responsibility to do all that is legally required and commercially reasonable to obtain and retain any governmental
approvals to manufacture and/or sell LICENSED PRODUCTS and/or use LICENSED PROCESSES for all 

  
 8 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
relevant activities of LICENSEE and SUBLICENSEES. If the commercialization of multiple LICENSED PRODUCTS or LICENSED PROCESSES is commercially reasonable, then the requirement of this paragraph
shall apply to all such LICENSED PRODUCTS and/or LICENSED PROCESSES. Further, for the sake of clarity, LICENSEE must make commercially reasonable amounts or levels of LICENSED PRODUCTS and/or LICENSED PROCESSES available. 

5.2 Without limiting Paragraph 5.1, LICENSEE agrees to reach the following commercialization and research and development milestones for the LICENSED PRODUCTS
and LICENSED PROCESSES (together the “MILESTONES”) by the following dates: 
 1) [XXX] 

2) [XXX] 
 3) [XXX] 

4) [XXX] 
 For the purposes of this Agreement,
initiation of a clinical trial shall mean that date upon which the first patient or subject is treated with a LICENSED PRODUCT under a protocol approved by an appropriate drug regulatory agency with a therapeutic agent or process that has been
manufactured according to Good Manufacturing Practices (GMP) guidelines provided by the relevant regulatory agency. 
 5.3 LICENSEE must achieve each
MILESTONE on or before the deadline dates indicated above. LICENSEE shall notify MICHIGAN within thirty (30) days after each such deadline as to whether or not such MILESTONE was met. If LICENSEE fails to meet any MILESTONE under this Article
by the date of any MILESTONE deadline, LICENSEE will be deemed to be in material breach of this Agreement, and MICHIGAN may terminate the Agreement effective on ninety (90) days’ written notice, unless LICENSEE achieves the MILESTONE
within this ninety (90) day period. 
 ARTICLE 6 - SUBLICENSING 

6.1 LICENSEE shall notify MICHIGAN in writing of every sublicense agreement and each amendment thereto within thirty (30) days after their execution, and
indicate the name of the SUBLICENSEE, the territory of the sublicense, the scope of the sublicense, and the nature, timing and amounts of all fees and royalties to be paid thereunder, and whether or not the SUBLICENSEE has greater or fewer than 500
employees. Upon request, LICENSEE shall provide MICHIGAN with a copy of sublicense agreements. 
 6.2 LICENSEE shall not receive from SUBLICENSEES anything
of value other than cash payments in consideration for any sublicense under this Agreement, without the express prior written permission of MICHIGAN. 

  
 9 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 6.3 Each sublicense granted by LICENSEE under this Agreement shall provide for its termination upon
termination of this Agreement. Each sublicense shall terminate upon termination of this Agreement unless LICENSEE has previously assigned its rights under the sublicense to MICHIGAN and MICHIGAN has agreed at its sole discretion in writing to such
assignment. 
 6.4 LICENSEE shall require that all sublicenses: (a) be consistent with the terms and conditions of this Agreement; (b) contain the
SUBLICENSEE’S acknowledgment of the disclaimer of warranty and limitation on MICHIGAN’s liability, as provided by Article 9 below; and (c) contain provisions under which the SUBLICENSEE accepts duties at least equivalent to those
accepted by the LICENSEE in the following Paragraphs: 4.4 (duty to keep records), 10.1 (duty to defend, hold harmless, and indemnify MICHIGAN), 10.3 (duty to maintain insurance), 13.4 (duty to properly mark LICENSED PRODUCTS with patent notices),
and 13.6 (duty to restrict the use of MICHIGAN’s name). 
 ARTICLE 7 - PATENT APPLICATIONS AND MAINTENANCE 

7.1 MICHIGAN shall have the right to control all aspects maintaining the patents that form the basis for the PATENT RIGHTS, including administrative
reexaminations and reviews, disputes (including litigation) regarding inventorship and derivation, and interferences. LICENSEE shall fully cooperate with MICHIGAN in activities relating to the PATENT RIGHTS, including said activities. Upon
MICHIGAN’s request, to the extent permitted by law, LICENSEE shall cooperate with MICHIGAN in applying for patent term extension for any and all patents included in the PATENT RIGHTS. LICENSEE and MICHIGAN will mutually agree on the
jurisdictions in which to seek such patent protection. 
 7.2 MICHIGAN shall notify LICENSEE of all information received by MICHIGAN relating to maintenance
of the PATENT RIGHTS, and shall make reasonable efforts to allow LICENSEE to review, comment, and advise upon such information. LICENSEE shall hold such information confidential and to use the information only for the purpose of advancing
MICHIGAN’s PATENT RIGHTS. 
 7.3 LICENSEE shall reimburse MICHIGAN for all fees and costs relating to the activities described in this Article;
provided, however, that LICENSEE shall not be responsible to reimburse such fees and cost relating to any country in which LICENSEE has not agreed to seek patent protection. Such reimbursement shall be made within thirty (30) days of receipt of
MICHIGAN’s invoice and shall be subject to the interest and other requirements specified in Article 4 above. 
 ARTICLE 8 -
ENFORCEMENT 
 8.1 Each party shall promptly advise the other in writing of any known acts of potential infringement of the PATENT RIGHTS by another
party. LICENSEE has the first option to police the PATENT RIGHTS against infringement by other parties within the TERRITORY and the FIELD OF USE, including those prior to the EFFECTIVE DATE. LICENSEE shall not file any suit without (a) first
performing a thorough, diligent investigation of the merits of such suit, including with respect to the validity and enforceability of the PATENT RIGHTS; (b) there being reasonable legal and economic bases for doing so; and (c) notifying
MICHIGAN twenty 

  
 10 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
days before any such filing. This right to police includes filing, prosecuting, and settling all infringement actions at its expense, except that LICENSEE shall make any such settlement only with
the advice and consent of MICHIGAN. LICENSEE has the right to file suit using counsel of its choosing, subject to MICHIGAN’s approval, which shall not be unreasonably withheld or delayed. LICENSEE may grant to third parties the right to enforce
hereunder, but only with the express written permission of MICHIGAN. 
 8.2 If LICENSEE has complied with Paragraph 8.1, MICHIGAN shall provide reasonable
assistance to LICENSEE with respect to such actions, but only if LICENSEE promptly reimburses MICHIGAN for out-of-pocket expenses incurred in connection with any such
assistance rendered at LICENSEE’s request or reasonably required by MICHIGAN, including but not limited to expenses incurred in complying with discovery duties. MICHIGAN retains the right to participate, with counsel of its own choosing and at
its own expense, in any action under this Article. LICENSEE shall defend, indemnify and hold harmless MICHIGAN with respect to any claims asserted by an alleged infringer reasonably related to the enforcement of the PATENT RIGHTS under this Article,
including but not limited to antitrust counterclaims and claims for recovery of attorney fees. 
 8.3 MICHIGAN and its employees have a vital interest in
lawsuits relating to the validity and enforceability of the PATENT RIGHTS. If a third party files a suit, including as a counterclaim, alleging that any of the PATENT RIGHTS is invalid or unenforceable, then the parties shall jointly control the
defense of such claim. Each party shall consult with the other with respect to the defense of such claim, and shall reasonably consider the other party’s input. In furtherance of such joint control, at the onset of such claim and as reasonable
during the pendency of any such claim, the parties shall meet and confer in good faith to set a plan for handling the defense thereof. The parties expect that in general (a) LICENSEE will have the right to lead daily activities, including but
not limited to discovery, relating to the defense and (b) the parties would make joint filings. Notwithstanding, in the event that the parties cannot agree on how to proceed with respect to such claim, MICHIGAN shall have the right to control
the defense thereof on either a temporary or permanent basis. LICENSEE shall be responsible for the reasonable costs and fees associated with the activities under this Paragraph 8.3. The parties shall consider reasonable controls on costs and fees
as part of an aforementioned meet and confer with respect to the handling of the defense. Notwithstanding, if a third party asserts jurisdiction for any such action solely as the result of acts of MICHIGAN, then MICHIGAN shall be responsible for
such reasonable costs and fees. LICENSEE shall have the right to offset [XXX] of any fees it is responsible for under this Section 8.3 from payments it is required to make to MICHIGAN under Section 3.1 hereof. 

8.4 If LICENSEE or MICHIGAN recovers damages in patent litigation or settlement thereof, the award shall be applied first to satisfy LICENSEE’s (to the
extent not offset in accordance with Section 8.3) and MICHIGAN’s reasonable expenses and legal fees for the litigation. The remaining balance shall be divided equally between LICENSEE and MICHIGAN. This provision shall control the division
of revenues where a sublicense, covenant not to sue, or assignment of rights is granted as part of a settlement of such lawsuit (including prospective rights). 

  
 11 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 ARTICLE 9 - NO WARRANTIES; LIMITATION ON MICHIGAN’S LIABILITY 

9.1 MICHIGAN makes no representations or warranties that any claim within the PATENT RIGHTS is or will be held valid, patentable, or enforceable, or that the
manufacture, importation, use, offer for SALE, SALE or other distribution of any LICENSED PRODUCTS or LICENSED PROCESSES will not infringe upon any patent or other rights. 

9.2 MICHIGAN MAKES NO REPRESENTATIONS, EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND ASSUMES NO RESPONSIBILITIES WHATEVER WITH RESPECT TO DESIGN, DEVELOPMENT, MANUFACTURE, USE, SALE OR OTHER DISPOSITION BY LICENSEE OR SUBLICENSEES OF
LICENSED PRODUCTS OR LICENSED PROCESSES. LICENSEE AND SUBLICENSEES ASSUME THE ENTIRE RISK AS TO PERFORMANCE OF LICENSED PRODUCTS AND LICENSED PROCESSES. 

9.3 In no event shall MICHIGAN be responsible or liable for any direct, indirect, special, incidental, or consequential damages or lost profits or other
economic loss or damage with respect to LICENSED PRODUCTS LICENSED PROCESSES, or the PATENT RIGHTS to LICENSEE, SUBLICENSEES or any other individual or entity regardless of legal or equitable theory. The above limitations on liability apply even
though MICHIGAN may have been advised of the possibility of such damage. 
 9.4 LICENSEE shall not make any statements, representations or warranties
whatsoever to any person or entity, or accept any liabilities or responsibilities whatsoever from any person or entity that are inconsistent with any disclaimer or limitation included in this Article 9. 

ARTICLE 10 - INDEMNITY; INSURANCE 
 10.1
LICENSEE shall defend, indemnify and hold harmless and shall require SUBLICENSEES to defend, indemnify and hold harmless MICHIGAN for and against any and all claims, demands, damages, losses, and expenses of any nature (including attorneys’
fees and other litigation expenses), resulting from, but not limited to, death, personal injury, illness, property damage, economic loss or products liability, including errors and omissions, arising from or in connection with, any of the following:
(1) Any manufacture, use, SALE or other disposition by LICENSEE, SUBLICENSEES or transferees of LICENSED PRODUCTS or LICENSED PROCESSES; (2) The use by any person of LICENSED PRODUCTS made, used, sold or otherwise distributed by LICENSEE
or SUBLICENSEES; and (3) The use or practice by LICENSEE or SUBLICENSEES of any invention or computer software related to the PATENT RIGHTS. 
 10.2
MICHIGAN is entitled to participate at its option and expense through counsel of its own selection, and may join in any legal actions related to any such claims, demands, damages, losses and expenses under Paragraph 10.1 above. LICENSEE shall not
settle any such legal action with an admission of liability of MICHIGAN without MICHIGAN’s written approval. 

  
 12 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 10.3 Prior to any distribution or commercial use of any LICENSED PRODUCT or use of any LICENSED PROCESS by
LICENSEE, LICENSEE shall purchase and maintain in effect commercial general liability insurance, product liability insurance, and errors and omissions insurance which shall protect LICENSEE and MICHIGAN with respect to the events covered by
Paragraph 10.1, and LICENSEE shall require the same of any SUBLICENSEE. Each such insurance policy must provide reasonable coverage for all claims with respect to any LICENSED PROCESS used and any LICENSED PRODUCTS manufactured, used, sold, licensed
or otherwise distributed by LICENSEE — or, in the case of a SUBLICENSEE’s policy, by said SUBLICENSEE — and must specify MICHIGAN as an additional insured. LICENSEE shall furnish certificate(s) of such insurance to MICHIGAN, upon
request. 
 10.4 In no event shall either party hereunder be liable to the other for any special, indirect, or consequential damages of any kind whatsoever
resulting from any breach or default of this Agreement. 
 ARTICLE 11 - TERM AND TERMINATION 

11.1 If LICENSEE ceases to operate its business, or if it files a petition in bankruptcy, has an involuntary petition in bankruptcy filed against LICENSEE
that is not dismissed within sixty days after the filing thereof, make a general assignment for the benefit of creditors or liquidates or dissolves, this Agreement shall immediately terminate upon MICHIGAN’s attempt to deliver a termination
notice to the address for notices provided herein. If LICENSEE makes or attempts to make an assignment for the benefit of creditors, or if proceedings in voluntary or involuntary bankruptcy or insolvency are instituted on behalf of or against
LICENSEE, or if a receiver or trustee is appointed for the property of LICENSEE, this Agreement shall automatically terminate. LICENSEE shall notify MICHIGAN of any such event mentioned in this Paragraph as soon as reasonably practicable, and in any
event within five days after any such event. 
 11.2 If LICENSEE fails to make any payment due to MICHIGAN, other than amounts subject to a bona fide
dispute, upon thirty (30) days’ written notice by MICHIGAN, this Agreement shall automatically terminate unless MICHIGAN specifically extends such date in writing or such unpaid amount is paid to MICHIGAN within such thirty (30) day
period. Such termination shall not foreclose MICHIGAN from collection of any amounts remaining unpaid or seeking other legal relief. 
 11.3 Upon any
material breach or default of this Agreement by LICENSEE (other than as specifically provided herein, the terms of which shall take precedence over the handling of any other material breach or default under this Paragraph), MICHIGAN has the right to
terminate this Agreement effective on ninety (90) days’ written notice to LICENSEE. Such termination shall become automatically effective upon expiration of the thirty-day period unless LICENSEE
cures the material breach or default before the period expires. 
 11.4 LICENSEE has the right to terminate this Agreement at any time on sixty
(60) days’ written notice to MICHIGAN if LICENSEE prior to the termination date: 
 (a) pays all amounts due MICHIGAN through the
effective date of the termination; 
 (b) submits a final report of the type described in Paragraph 4.2; 

  
 13 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 (c) returns any patent documentation (including that exchanged under Article 7) and any other
confidential or trade-secret materials provided to LICENSEE by MICHIGAN in connection with this Agreement, or, with prior approval by MICHIGAN, destroys such materials, and certifies in writing that such materials have all been returned or
destroyed; and 
 (d) suspends its manufacture, use and SALE of the LICENSED PROCESS(ES) and LICENSED PRODUCT(S). 

11.5 Upon any termination of this Agreement, and except as provided herein to the contrary, all rights and obligations of the parties hereunder shall cease,
except any previously accrued rights and obligations and further as follows: (a) obligations to pay royalties and other sums, or to transfer equity or other consideration, accruing hereunder up to the day of such termination, whether or not
this Agreement provides for a number of days before which actual payment is due and such date is after the day of termination and whether or not a required funding event or other stock transfer trigger has yet been met; (b) MICHIGAN’s
rights to inspect books and records as described in Article 4, and LICENSEE’s obligations to keep such records for the required time; 
 (c) any cause
of action or claim of LICENSEE or MICHIGAN accrued or to accrue because of any breach or default by the other party hereunder; (d) the provisions of Articles 1, 9, 10, and 13; and (e) all other terms, provisions, representations, rights
and obligations contained in this Agreement that by their sense and context are intended to survive until performance thereof by either or both parties. 

Termination by either party hereunder shall not alter or affect any other rights or relief that either party may be entitled to under law. 

11.6 Upon termination of this Agreement, if LICENSEE has filed patent applications or obtained patents to any modification or improvement to LICENSED PRODUCTS
or LICENSED PROCESSES within the scope of the PATENT RIGHTS, LICENSEE agrees upon request to enter into good faith negotiations with MICHIGAN or MICHIGAN’s future licensee(s) for the purpose of granting licensing rights to said modifications or
improvements in a timely fashion and under commercially reasonable terms. 
 11.7 If LICENSEE or a SUBLICENSEE, or any affiliate thereof, asserts the
invalidity or unenforceability of any claim included in the PATENT RIGHTS, including by way of litigation or administrative proceedings, either directly or through any other party, then MICHIGAN shall have the right to immediately terminate this
Agreement upon written notice to LICENSEE. 
 ARTICLE 12 - NOTICES 

12.1 Any notice, request, or report required or permitted to be given or made under this Agreement by either party is effective when mailed if sent by
recognized overnight carrier, certified or registered mail, or electronic mail followed by confirmation by U.S. mail, to the address set forth below or such other address as such party specifies by written notice given in conformity herewith. Any
notice, request, or report not so given is not effective until actually received by the other party. 

  
 14 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

			
	To MICHIGAN:	  	To LICENSEE:
		
	 Office of Technology Transfer
 University of
Michigan
 1600 Huron Parkway, 2nd Floor
 Ann Arbor, MI
48109-2590
	  	 Solid GT, LLC
 One Broadway

Cambridge, MA 02142
 Attention: Ilan Ganot, CEO

 ARTICLE 13 - MISCELLANEOUS PROVISIONS 

13.1 This Agreement shall be governed by and construed under the laws of the state of Michigan without regard for principles of choice of law, except that
questions affecting the construction and effect of any patent shall be determined by the law of the country in which the patent was granted. Any claims, demands, or actions asserted against MICHIGAN, its Regents, fellows, officers, employees or
agents shall only be brought in the Michigan Court of Claims. LICENSEE, its successors, and assigns consent to the jurisdiction of a court with applicable subject matter jurisdiction sitting in the state of Michigan with respect to any claims
arising under this agreement or the relationship between the parties. 
 13.2 MICHIGAN and LICENSEE agree that this Agreement sets forth their entire
understanding concerning the subject matter of this Agreement. The parties may amend this Agreement from time to time, such as to add new rights, but no modification will be effective unless both MICHIGAN and LICENSEE agree to it in writing. 

13.3 If a court of competent jurisdiction finds any term of this Agreement invalid, illegal or unenforceable, that term will be curtailed, limited or deleted,
but only to the extent necessary to remove the invalidity, illegality or unenforceability, and without in any way affecting or impairing the remaining terms. 

13.4 LICENSEE agrees to mark the LICENSED PRODUCTS sold in the United States with all applicable United States patent numbers as necessary to meet the
requirements of 35 U.S.C. 287 so that the full benefits of patent enforcement may be realized. All LICENSED PRODUCTS shipped to or sold in other countries shall be marked to comply with the patent laws and practices of the countries of manufacture,
use and SALE. 
 13.5 No waiver by either party of any breach of this Agreement, no matter how long continuing or how often repeated, is a waiver of any
subsequent breach thereof, nor is any delay or omission on the part of either party to exercise or insist on any right, power, or privilege hereunder a waiver of such right, power or privilege. In no event shall any waiver be deemed valid unless it
is in writing and signed by an authorized representative of each party. 
 13.6 LICENSEE shall, and shall require its affiliates to, refrain from using and
to require SUBLICENSEES to refrain from using the name of MICHIGAN or its employees in publicity or advertising without the prior written approval of MICHIGAN. Reports in scientific literature and presentations of joint research and development work
are not publicity. Notwithstanding this provision, without prior written approval of MICHIGAN, LICENSEE and SUBLICENSEES 

  
 15 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
may state publicly that LICENSED PRODUCTS and PROCESSES were developed by LICENSEE based upon an invention(s) developed at the University of Michigan and/or that the PATENT RIGHTS were licensed
from the University of Michigan. 
 13.7 LICENSEE agrees to comply with all applicable laws and regulations, including but not limited to all United States
laws and regulations controlling the export of commodities and technical data. LICENSEE shall be solely responsible for any violation of such laws and regulations involving LICENSEE or its SUBLICENSEES, and to defend, indemnify and hold harmless
MICHIGAN if any legal action of any nature results from any such violation. 
 13.8 The relationship between the parties is that of independent contractor
and contractee. Neither party is an agent of the other in connection with the exercise of any rights hereunder, and neither has any right or authority to assume or create any obligation or responsibility on behalf of the other. 

13.9 LICENSEE may not assign this Agreement without the prior written consent of MICHIGAN and shall not pledge any of the license rights granted in this
Agreement as security for any creditor. Any attempted pledge of any of the rights under this Agreement or assignment of this Agreement without the prior consent of MICHIGAN will be void from the beginning. No assignment by LICENSEE will be effective
until the intended assignee agrees in writing to accept all of the terms and conditions of this Agreement, and such writing is provided to MICHIGAN. Notwithstanding the foregoing, LICENSEE may, without MICHIGAN’s consent, assign its rights
under this Agreement to a purchaser of all or substantially all of LICENSEE’s business relating to the subject matter of this Agreement, so long as (a) LICENSEE is not in breach of this Agreement and (b) such assignee provides a
statement in writing to MICHIGAN that it agrees to accept all the terms and conditions of this Agreement (including obligations existing as of the time of such assignment) in the place of LICENSEE. 

13.10 If the registration, recordation, or reporting to a national or supranational agency of this Agreement, its terms, or assignment thereof is or becomes
required or advisable (e.g., as a prerequisite to enforceability of the Agreement in such nation), LICENSEE shall, at its expense, promptly undertake such action. LICENSEE shall provide prompt notice thereof to MICHIGAN along with copies of relevant
documentation. 

  
 16 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement in duplicate originals by their duly
authorized officers or representatives. 
  

									
	 FOR LICENSEE:
 SOLID GT,
LLC
	 		 	FOR THE REGENTS OF THE UNIVERSITY OF MICHIGAN
					
	By	 	 /s/ Ilan Ganot
	 		 	By	 	 /s/ Ruth L. Rasor

		 	(authorized representative)	 		 		 	Ruth L. Rasor
	Printed Name	 	 Ilan Ganot
	 		 		 	 Managing Director of Licensing
 UM
Technology Transfer

	Title	 	 CEO
	 		 		 	
	Date	 	 3/11/16
	 		 	Date	 	 14 March 2016

  
 17 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}]]